Liminatus Pharma (NASDAQ:LIMN) Stock Rating Lowered by Wall Street Zen

Liminatus Pharma (NASDAQ:LIMN) was downgraded by equities research analysts at Wall Street Zen to a “strong sell” rating in a research note issued to investors on Saturday.

Separately, Weiss Ratings upgraded Liminatus Pharma from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company has an average rating of “Sell”.

Liminatus Pharma Stock Performance

Shares of LIMN opened at $5.16 on Friday. Liminatus Pharma has a 52 week low of $4.75 and a 52 week high of $203.00. The stock has a market capitalization of $5.21 million, a price-to-earnings ratio of -0.22 and a beta of 5.34. The stock has a fifty day moving average of $5.84 and a 200-day moving average of $11.69.

Liminatus Pharma (NASDAQ:LIMN) last released its quarterly earnings data on Friday, August 14th. The company reported ($1.50) earnings per share for the quarter.

About Liminatus Pharma

Liminatus Pharma, Inc is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.